MARKET

BNR

BNR

Burning Rock Biotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

36.15
-0.49
-1.34%
Opening 09:44 01/25 EST
OPEN
37.10
PREV CLOSE
36.64
HIGH
37.65
LOW
35.60
VOLUME
33.77K
TURNOVER
--
52 WEEK HIGH
37.97
52 WEEK LOW
18.64
MARKET CAP
3.69B
P/E (TTM)
-55.5470
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Burning Rock (BNR) in Focus: Stock Moves 5.4% Higher
Zacks.com · 3d ago
Burning Rock (BNR) in Focus: Stock Moves 5.4% Higher
Burning Rock (BNR) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Zacks · 3d ago
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 19)
Benzinga · 5d ago
OncoCyte's stock soars after licensing deal with China-based company, days after insiders acquired shares
MarketWatch · 12/15/2020 13:18
Oncocyte, Burning Rock Execute Strategic Agreement To Distribute DetermaRX In China
Oncocyte and Burning Rock Execute Strategic Agreement to Distribute DetermaRx in China Aligns Oncocyte with one of China's fastest growing NGS-based cancer therapy selection companies; China is considered to be
Benzinga · 12/15/2020 13:14
Oncocyte and Burning Rock Execute Strategic Agreement to Distribute DetermaRx in China
Aligns Oncocyte with one of China’s fastest growing NGS-based cancer therapy selection companies; China is considered to be the world’s largest early-stage lung cancer market Exclusive agreement includes payments of up to $6M in the first year and ongoing...
GlobeNewswire · 12/15/2020 13:00
The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 14)
Benzinga · 12/15/2020 12:52
Burning Rock inks license pact with Oncocyte Corporation
Burning Rock Biotech (BNR) has entered into an exclusive licensing agreement with Oncocyte Corporation (OCX) to bring DetermaRx, a treatment stratification test that identifies stage I-IIA non-small cell lung cancer patients at
Seekingalpha · 12/15/2020 11:08
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BNR. Analyze the recent business situations of Burning Rock Biotech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BNR stock price target is 36.00 with a high estimate of 40.96 and a low estimate of 31.04.
EPS
Institutional Holdings
Institutions: 57
Institutional Holdings: 15.92M
% Owned: 15.61%
Shares Outstanding: 101.99M
TypeInstitutionsShares
Increased
8
1.28M
New
33
12.42K
Decreased
8
1.11M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BNR
Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The Company operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The Company mainly conducts its businesses in the China market.
More

Webull offers kinds of Burning Rock Biotech Ltd(ADR) stock information, including NASDAQ:BNR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BNR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BNR stock methods without spending real money on the virtual paper trading platform.